TOP TEN perturbations for 39474_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39474_s_at
Selected probe(set): 218468_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39474_s_at (218468_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):-8.636739
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-18)
	Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):-8.495178
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-215)
	Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):-8.487252
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-319)
	Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):-8.408718
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-229)
	Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):7.724938
Number of Samples:2 / 4

Experimental	lung cancer study 1 (PDX; non-small cell carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):7.7025146
Number of Samples:2 / 3

Experimental	lung cancer study 1 (PDX; non-small cell carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; basaloid carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):-7.549462
Number of Samples:43 / 2

Experimental	lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; non-small cell carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):7.547381
Number of Samples:2 / 22

Experimental	lung cancer study 1 (PDX; non-small cell carcinoma; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control	lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

uterine/pelvic pathology study 2 (mid-se MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):-7.30408
Number of Samples:14 / 2

Experimental	uterine/pelvic pathology study 2 (mid-se MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the mid-secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control	uterine/pelvic pathology study 2 (late se MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

uterine/pelvic pathology study 2 (late se MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):7.093285
Number of Samples:2 / 6

Experimental	uterine/pelvic pathology study 2 (late se MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control	uterine/pelvic pathology study 2 (early se MCP)
	Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.